The Latest Treatment Strategies for Henoch-Schönlein Purpura Nephritis: Application of Immunosuppressants

Baichi Chen; Manqiong Yang; Yaoxue Zeng; Hao Feng

doi:10.54097/b32nxx56

Authors

Baichi Chen
Manqiong Yang
Yaoxue Zeng
Hao Feng

DOI:

https://doi.org/10.54097/b32nxx56

Keywords:

Henoch-Schönlein Purpura, Immunosuppressants, Clinical Treatment, HSP Nephritis

Abstract

Henoch-Schönlein purpura (HSP) is a common vasculitis in children, primarily characterized by skin purpura, abdominal pain, joint pain, and kidney involvement. In recent years, immunosuppressants have gained increasing attention in treating HSP nephritis, especially for severe cases and patients with persistent symptoms. This review summarizes the current applications, efficacy assessments, and potential side effects of immunosuppressants in patients with HSP nephritis, aiming to provide a reference for clinical treatment.

Downloads

Download data is not yet available.

References

[1] Micheletti RG, Werth VP. Small vessel vasculitis of the skin. Rheum Dis Clin North Am. 2015. 41(1): 21-32, vii.

[2] Chen JY, Mao JH. Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management. World J Pediatr. 2015. 11(1): 29-34.

[3] Nikolaishvili M, Pazhava A, Di Lernia V. Viral Infections May Be Associated with Henoch-Schönlein Purpura. J Clin Med. 2023. 12(2): 697.

[4] Nicoara O, Twombley K. Immunoglobulin A Nephropathy and Immunoglobulin A Vasculitis. Pediatr Clin North Am. 2019. 66(1): 101-110.

[5] Willey CJ, Coppo R, Schaefer F, Mizerska-Wasiak M, Mathur M, Schultz MJ. The incidence and prevalence of IgA nephropathy in Europe. Nephrol Dial Transplant. 2023. 38(10): 2340-2349.

[6] Kanigicherla D, Hamilton P, Czapla K, Brenchley PE. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy. Nephrology (Carlton). 2018. 23(1): 60-68.

[7] KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021. 100(4S): S1-S276.

[8] Wang D, Liu T, Lu J, Li X, Liu X, Xu W. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide therapy for Henoch schonlein purpura nephritis in children: A meta-analysis. Medicine (Baltimore). 2024. 103(30): e39059.

[9] Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000. 47(2-3): 85-118.

[10] [Evidence-based guideline for diagnosis and treatment of Henoch-Schonlein purpura nephritis (2016)]. Zhonghua Er Ke Za Zhi. 2017. 55(9): 647-651.

[11] Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford). 2019. 58(9): 1607-1616.

[12] Abu-Zaid MH, Salah S, Lotfy HM, et al. Consensus evidence-based recommendations for treat-to-target management of immunoglobulin A vasculitis. Ther Adv Musculoskelet Dis. 2021. 13: 1759720X211059610.

[13] Yang X, Li Q, He Y, et al. Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis. Front Pharmacol. 2022. 13: 956397.

[14] Schinzel V, Fernandez JD, Clemente G, et al. The profile and clinical outcomes of patients with renal involvement due to IgA vasculitis: is azathioprine a good option for treatment. Adv Rheumatol. 2019. 59(1): 21.

[15] Chen ZY, Zhu YH, Zhou LY, et al. Association Between Genetic Polymorphisms of Metabolic Enzymes and Azathioprine-Induced Myelosuppression in 1,419 Chinese Patients: A Retrospective Study. Front Pharmacol. 2021. 12: 672769.

[16] W-Y L, Ong CP, P-HH C, et al. Nsp1 facilitates SARS-CoV-2 replication through calcineurin-NFAT signaling. mBio. 2024. 15(4): e0039224.

[17] Koskela M, Jahnukainen T, Endén K, et al. Methylprednisolone or cyclosporine a in the treatment of Henoch-Schönlein nephritis: a nationwide study. Pediatr Nephrol. 2019. 34(8): 1447-1456.

[18] Ihm HS, Lee JY, Hwang HS, et al. Combination therapy of low-dose cyclosporine and steroid in adults with IgA nephropathy . Clin Nephrol. 2019. 92(3): 131-140.

[19] Phan K, Charlton O, Baker C, Foley P, Smith SD. Dermatologist attitudes toward ciclosporin use in atopic dermatitis. J Dermatolog Treat. 2021. 32(8): 922-924.

[20] Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother. 2008. 9(4): 635-43.

[21] Yan Z, Wang J, Huang T, Liu X, Wang L, Xu G. Effectiveness and safety of tacrolimus treatment for IgA nephropathy: A prospective cohort study. Med Clin (Barc). 2022. 158(12): 596-602.

[22] Wu D, Ma R, Wang X, Yang Y. Efficacy and Safety of Tacrolimus in the Treatment of Pediatric Henoch-Schönlein Purpura Nephritis. Paediatr Drugs. 2022. 24(4): 389-401.

[23] Yokota S. Mizoribine: mode of action and effects in clinical use. Pediatr Int. 2002. 44(2): 196-8.

[24] Mima A. Efficacy of mizoribine and prednisolone combination therapy in adult patients with IgA vasculitis. Rheumatol Int. 2017. 37(8): 1387-1393.

[25] Kawakami T, Shirai S, Kimura K, Soma Y. Successful use of mizoribine to treat recurrent corticosteroid-resistant palpable purpura in a patient with henoch-schonlein purpura nephritis. Arch Dermatol. 2010. 146(2): 212-3.

[26] Hou L, Zhang Z, Du Y. Leflunomide therapy for IgA vasculitis with nephritis in children. BMC Pediatr. 2021. 21(1): 391.

[27] Lou T, Wang C, Chen Z, et al. Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy. Nephrology (Carlton). 2006. 11(2): 113-6.

[28] Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target. Autoimmun Rev. 2013. 12(8): 835-8.

[29] Hernández-Rodríguez J, Carbonell C, Mirón-Canelo JA, Diez-Ruiz S, Marcos M, Chamorro AJ. Rituximab treatment for IgA vasculitis: A systematic review. Autoimmun Rev. 2020. 19(4): 102490.

[30] Fenoglio R, Sciascia S, Naretto C, et al. Rituximab in severe immunoglobulin-A vasculitis (Henoch-Schönlein) with aggressive nephritis. Clin Exp Rheumatol. 2020. 38 Suppl 124(2): 195-200.